Scalability and process transfer of mesenchymal stromal cell production from monolayer to microcarrier culture using human platelet lysate

Cytotherapy

Volumn 18, Issue 4, 2016, Pages 523-535

  Heathman, Thomas R J ^a,b   Stolzing, Alexandra ^b,c   Fabian, Claire ^c,d   Rafiq, Qasim A ^b,e   Coopman, Karen ^b   Nienow, Alvin W ^b,e,f   Kara, Bo ^g   Hewitt, Christopher J ^b,e  

^a PCT a Caladrius Company   (United States)

^b LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

^e ASTON UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g Fujifilm Diosynth Biotechnologies   (United Kingdom)

Author keywords

Bioprocess; Cell based therapy; Comparability; Harvest; Human platelet lysate; Manufacture; Mesenchymal stromal cell; Microcarrier expansion; Process development; Process transfer

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1; OCTAMER TRANSCRIPTION FACTOR 4;

ARTICLE; BONE DEVELOPMENT; CELL AGING; CELL CYCLE; CELL EXPANSION; CELL FUNCTION; CELL GROWTH; CELL LYSATE; CELL POPULATION; CELL TRANSFER; CELLULAR PARAMETERS; COLONY FORMATION; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; MESENCHYMAL STROMA CELL; MICROCARRIER CULTURE; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL SELF-RENEWAL; ANIMAL; BOVINE; CELL CULTURE; CELL CULTURE TECHNIQUE; CELL PROLIFERATION; CYTOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROTECHNOLOGY; PROCEDURES; THROMBOCYTE; TISSUE SCAFFOLD; TRANSLATIONAL RESEARCH;

ANIMALS; BLOOD PLATELETS; CATTLE; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICROTECHNOLOGY; TISSUE SCAFFOLDS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84960131813     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2016.01.007     Document Type: Article

References (38)

1. Heathman T.R.J., Nienow A.W., McCall M.J., Coopman K., Kara B., Hewitt C.J. The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen Med 2015, 10:49-64.
2. Carmen J., Burger S.R., McCaman M., Rowley J.A. Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development. Regen Med 2012, 7:85-100.
3. Rowley J., Abraham E., Campbell A., Brandwein H., Oh S. Meeting lot-size challenges of manufacturing adherent cells for therapy. BioProc Int 2012, 10:16-22.
4. Rafiq Q.A., Brosnan K.M., Coopman K., Nienow A.W., Hewitt C.J. Culture of human mesenchymal stem cells on microcarriers in a 5 l stirred-tank bioreactor. Biotechnol Lett 2013, 35:1233-1245.
5. Simaria A.S., Hassan S., Varadaraju H., Rowley J., Warren K., Vanek P., et al. Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies. Biotechnol Bioeng 2014, 111:69-83.
6. Nienow A.W. Reactor engineering in large scale animal cell culture. Cytotechnology 2006, 50:9-33.
7. Wappler J., Rath B., Laufer T., Heidenreich A., Montzka K. Eliminating the need of serum testing using low serum culture conditions for human bone marrow-derived mesenchymal stromal cell expansion. Biomed Eng Online 2013, 12:15.
8. Brindley D.A., Davie N.L., Culme-Seymour E.J., Mason C., Smith D.W., Rowley J.A. Peak serum: implications of serum supply for cell therapy manufacturing. Regen Med 2012, 7:7-13.
9. Kocaoemer A., Kern S., Kluter H., Bieback K. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007, 25:1270-1278.
10. Lubkowska A., Dolegowska B., Banfi G. Growth factor content in PRP and their applicability in medicine. J Biol Regul Homeost Agents 2012, 26. 3S-22.
11. Schallmoser K., Bartmann C., Rohde E., Bork S., Guelly C., Obenauf A.C., et al. Replicative senescence-associated gene expression changes in mesenchymal stromal cells are similar under different culture conditions. Haematologica 2010, 95:867-874.
12. Doucet C., Ernou I., Zhang Y., Llense J.R., Begot L., Holy X., et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005, 205:228-236.
13. Heathman T.R.J., Rafiq Q.A., Chan A.K.C., Coopman K., Nienow A.W., Kara B., et al. Characterization of human mesenchymal stem cells from multiple donors and the implications for large scale bioprocess development. Biochem Eng J 2016, 108:14-23.
14. Nienow A.W., Rafiq Q.A., Coopman K., Hewitt C.J. A potentially scalable method for the harvesting of hMSCs from microcarriers. Biochem Eng J 2014, 85:79-88.
15. Nienow A.W., Hewitt C.J., Heathman T.R.J., Glyn V.A.M., Fonte G.N., Hanga M.P., et al. Agitation conditions for the culture and detachment of hMSCs from microcarriers in multiple bioreactor platforms. Biochem Eng J 2016, 108:24-29.
16. Heathman T.R.J., Stolzing A., Fabian C., Rafiq Q.A., Coopman K., Nienow A.W., et al. Serum-free process development: improving the yield and consistency of human mesenchymal stromal cell production. Cytotherapy 2015, 17:1524-1535.
17. Chan A.K., Heathman T.R., Coopman K., Hewitt C.J. Multiparameter flow cytometry for the characterisation of extracellular markers on human mesenchymal stem cells. Biotechnol Lett 2014, 36:731-741.
18. Izadpanah R., Kaushal D., Kriedt C., Tsien F., Patel B., Dufour J., et al. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res 2008, 68:4229-4238.
19. Naing M.W., Gibson D.A., Hourd P., Gomez S.G., Horton R.B., Segal J., et al. Improving umbilical cord blood processing to increase total nucleated cell count yield and reduce cord input wastage by managing the consequences of input variation. Cytotherapy 2015, 17:58-67.
20. Sunil N., Punreddy S., Niss K., Jing D. Expansion of human mesenchymal stem cells: using microcarriers and human platelet lysate. BioProc Int 2014, 12:74-78.
21. Heathman T.R.J., Glyn V.A.M., Picken A., Rafiq Q.A., Coopman K., Nienow A.W., et al. Expansion, harvest and cryopreservation of human mesenchymal stem cells in a serum-free microcarrier process. Biotechnol Bioeng 2015, 112:1696-1707.
22. Higuera G.A., Schop D., Spitters T.W., van Dijkhuizen-Radersma R., Bracke M., de Bruijn J.D., et al. Patterns of amino acid metabolism by proliferating human mesenchymal stem cells. Tissue Eng Part A 2012, 18:654-664.
23. Stolzing A., Scutt A. Age-related impairment of mesenchymal progenitor cell function. Aging Cell 2006, 5:213-224.
24. von Bahr L., Batsis I., Moll G., Hagg M., Szakos A., Sundberg B., et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 2012, 30:1575-1578.
25. Jung S., Panchalingam K.M., Rosenberg L., Behie L.A. Ex vivo expansion of human mesenchymal stem cells in defined serum-free media. Stem Cells Int 2012, 2012:21.
26. Yamachika E., Iida S. Bone regeneration from mesenchymal stem cells (MSCs) and compact bone-derived MSCs as an animal model. Jpn Dent Sci Rev 2013, 49:35-44.
27. Moll G., Alm J.J., Davies L.C., von Bahr L., Heldring N., Stenbeck-Funke L., et al. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?. Stem Cells 2014, 32:2430-2442.
28. Kirouac D.C., Zandstra P.W. The systematic production of cells for cell therapies. Cell Stem Cell 2008, 3:369-381.
29. dos Santos F., Andrade P.Z., Abecasis M.M., Gimble J.M., Chase L.G., Campbell A.M., et al. Toward a clinical-grade expansion of mesenchymal stem cells from human sources: a microcarrier-based culture system under xeno-free conditions. Tissue Eng Part C Methods 2011, 17:1201-1210.
30. Chen A.K.-L., Reuveny S., Oh S.K.W. Application of human mesenchymal and pluripotent stem cell microcarrier cultures in cellular therapy: achievements and future direction. Biotechnol Adv 2013, 31:1032-1046.
31. Mitchell P.D., Ratcliffe E., Hourd P., Williams D.J., Thomas R.J. A quality-by-design approach to risk reduction and optimization for human embryonic stem cell cryopreservation processes. Tissue Eng Part C Methods 2014, 20:941-950.
32. Bieback K. Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures. Transfus Med Hemother 2013, 40:326-335.
33. Gao T., Zhang N., Wang Z., Wang Y., Liu Y., Ito Y., et al. Biodegradable microcarriers of poly(lactide-co-glycolide) and nano-hydroxyapatite decorated with igf-1 via polydopamine coating for enhancing cell proliferation and osteogenic differentiation. Macromol Biosci 2015, 15(8):1070-1080.
34. Williams D.J., Thomas R.J., Hourd P.C., Chandra A., Ratcliffe E., Liu Y., et al. Precision manufacturing for clinical-quality regenerative medicines. Philos Transact A Math Phys Eng Sci 2012, 370:3924-3949.
35. Hampson B. Closed processing for cell therapies: engineering risk reduction and patient safety during manufacturing. Genet Eng Biotechnol News 2014, 34.
36. Pattappa G., Heywood H.K., de Bruijn J.D., Lee D.A. The metabolism of human mesenchymal stem cells during proliferation and differentiation. J Cell Physiol 2011, 226:2562-2570.
37. Heathman T. Development of a controlled bioreactor process to drive the consistent manufacture of human mesenchymal stem cells from multiple donors. Cytotherapy 2015, 17:S81-2.
38. Archibald P.R.T., Chandra A., Thomas D., Morley G., Lekishvili T., Devonshire A., et al. Comparability of scalable, automated hMSC culture using manual and automated process steps. Biochem Eng J 2015, 10.1016/j.bej.2015.07.001.